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Poster Session I S243syndrome/secondary AML (5), Non-Hodgkin’s Lymphoma (4), or
CML (3). There were 22 males, 9 females, ages 2 – 17 yrs, median
11. Ten patients (pts) had previously undergone myeloablative ther-
apy and HSCT, 8 pts had comorbid conditions increasing their risk
for treatment failure. Stem cell sources included 16 unrelated donors
(URD), 13 matched sibs and 2 mis-matched relatives. 29 of 31 HSC
donations were from mobilized peripheral blood and 2 were marrow.
Graft-versus-host disease (GVHD) prophylaxis was cyclosporine A
(CsA) alone in 9 pts and CsA and mycophenolate in 22 pts. Median
time to an ANC .500/mcl was 18 days and unsupported platelet
count .20,000/mcl was (28 pts) 17 days, 7 pts required no platelet
support. One pt failed to engraft and 3 had secondary graft loss. 6
pts developed Grade III-IV acute GVHD, 14 of the 24 pts surviving
more than 100 days developed chronic GVHD (8 limited, 6 exten-
sive). 16 pts survive, 10 without disease relapse or progression.
100-day mortality (7 of 31, 23%) was from infection (3), GVHD
(3) and relapse (1). 8 of 19 pts with matched donors relapsed, 2
died of infections complicating GVHD whereas 3 of 12 pts with mis-
matched donors relapsed, 7 died of complications: infection, GVHD
or graft failure.
RFS for patients HLA-matched at the allele (8 of 8) level was 42%
vs 18% (p5 0.04) with$ 1 mismatch while Overall Survival was
64% vs 24% (p5 0.02). Our results suggest RIC allogeneic HSCT
should be considered for pediatric pts with hematologic malignan-
cies, especially if a well-matched (related or unrelated) donor can
be identified. Our current studies are focused on reducing the toxic-
ity for recipients of mismatched grafts.
Patient Characteristics (n5 31)
Age—yrs, (median, std dev) 11 1/- 4
M – F 22 – 9
Prior Autologous HSCT 6
Prior Allogeneic HSCT 4
Matched Sib HSC 13URD or mm Relative HSC 18
HSC Dose–CD341 cells/kg, x10e6 (median,
std dev)8.8 1/- 5.7229
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CHD is the most common birth defect in the US. Improved sup-
portive care has resulted in more pediatric and adult survivors who
may develop indications for HSCT. We hypothesized there would
be overrepresentation of CHD in children undergoing HSCT, as
several inherited immune and bone marrow (BM) failure disorders
are associated with an increased CHD prevalence. As HSCT out-
comes of patients (pts) with CHD are not well known, we conducted
a retrospective chart review of 1185 sequential HSCT on 1031 pts
performed at Children’s Hospital Boston from 1989-2007. We
found 10 pts with major cardiac structural defects requiring surgical
catheterization or intervention for repair or palliation. Cardiac char-
acteristics are outlined in the table. 8 pts underwent allogeneic
HSCT for ALL (n5 4), AML (n5 1), CML (n5 1), Diamond-
Blackfan anemia (n5 1), and DiGeorge syndrome (n5 1) using
BM from matched sibling (n5 4) or unrelated donors (n5 3). 1 pt
received fresh T cells from a haploidentical donor. 2 pts underwent
autologous HSCT using BM for ALL (n5 1) and AML (n5 1).
Conditioning was cyclophosphamide (CY) and TBI +/- other che-
motherapy (n5 7) or CY +/- other chemotherapy (n5 2). The hap-
loidentical HSCT was performed without conditioning. GVHD
prophylaxis was cyclosporine and methotrexate, plus corticosteroids
for some unrelated BM recipients. Median time to absolute neutro-
phil count of 500/uL was 25 days (D, range 17-50). 2/8 allogeneic
HSCT recipients developed acute GVHD (1 Grade 2, 1 Grade 3).
1 received systemic corticosteroids. 50% of pts developed febrile
neutropenia. 2 had documented bacteremia, but no endocarditis or
life-threatening infectious toxicity was seen. Combined rates of
grade 3, 4, and 5 cardiac, pulmonary, and renal toxicities (NIH
CTC v. 3) through D + 100 were 10%, 10%, and 0%, respectively.
No pts died in the first 100 D post-HSCT. Pt follow-up ranged0.44-9.25 yrs (median 3.9yrs). 5 pts died at a median of 690D (range
159-780) of relapse (n5 4) and pulmonary hemorrhage (n5 1). 5 pts
underwent post-HSCT cardiac repair. 4 procedures were completed
uneventfully; 1 pt died of sepsis and pulmonary hemorrhage. Overall
CHD rates were 2-5  greater in our pts than US rates. We found
promising acute and long-term HSCT outcomes for children with
CHD, who readily tolerated HSCT associated volume challenges,
febrile neutropenia, and regimen-related toxicity, and suggest that
children with CHD should not be excluded from HSCT solely
due to their cardiac anomalies.
Cardiac Status on Admission
AgePatient
T
pat
rans-
lantCardiac
DiagnosisPrior
SurgeryPrior
AnthracyclineChronic
Cardiac
Rx1 2.5 Complex single
right ventricle
Bidirectional
Glenn shunt
No Enalapril,
aspirin2 5.3 Coarctation,
patent ductus
arteriosus
None Doxorubicin
60 mg/m2 1
dexrazoxane
None3 8.9 Truncus
Arteriosus Type
1A, ventricular
septal defect
Truncus repair No Enalapril4 13.9 Atrial septal
defect
None Daunorubicin
135 mg/m2
None5 0.3 Tetralogy of
Fallot
Tetralogy of
Fallot repair
No Digoxin6 8 Pulmonary
stenosis
Pulmonary
balloon
valvuloplasty
Doxorubicin
60 mg/m2
None7 10.6 Atrioventricular
canal defect
Atrioventricular
canal defect
repair
Doxorubicin* None8 18.5 Primum atrial
septal defect, cleft
mitral valve
None Daunorubicin
135 mg/m2
None9 1.5 Bicommissural
aortic valve,
coarctation,
mitral stenosis,
ventricular septal
defect
None Daunorubicin
128 mg/m2;
Idarubicin
30.6 mg/m2
None10 6.3 D-loop
transposition of
the great arteries,
ventricular septal
defect, pulmonary
stenosis
Blalock-Taussig
shunt, Rastelli
procedure,
conduit
revision,
pulmonary
valve
replacement
Doxorubicin
60 mg/m2 1
dexrazoxane
Aspirin*Initial care at outside institution, cannot confirm dose.230
RISK ADAPTED ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT)
FOR ACQUIRED SEVERE APLASTIC ANEMIA (SAA) IN PEDIATRIC RECIPI-
ENTS: IMPROVED OUTCOMES WITH UNRELATED DONORS
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Background: AlloSCT from matched sibling donors (MSD) has re-
sulted in the highest survival rates in children and adolescents with
